Telix is a global, commercial-stage biopharmaceutical company focused on the development of diagnostic and therapeutic (‘theranostic’) products using targeted radiation.

2020年11月1日 · Telix是一家专注于RDC的生物技术公司，总部位于澳大利亚墨尔本，聚焦新型放射性核素-靶向分子药物偶联技术，并利用这一 创新技术 平台开展RDC在癌症治疗、诊断领域的开发及应用。

Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Gozellix® (TLX007-CDx, kit for the preparation of gallium-68 (68 Ga) gozetotide injection), Telix’s next-generation PSMA-PET imaging [1] agent for prostate cancer.

Telix is focused on developing therapies for urologic (prostate and kidney), neurologic (brain) and musculoskeletal (sarcoma) cancers. The Precision Medicine unit support the Therapeutics unit by enabling the delivery of personalised theranostic solutions to market using Telix’s diagnostics.

Telix Pharmaceuticals的研发管线旨在解决前列腺癌、肾癌（肾癌）、脑癌（胶质母细胞瘤）和血液系统癌症（骨髓调节）以及一系列免疫和罕见疾病中未满足的重大医疗需求。

2024年6月10日 · Telix Pharmaceuticals的技术使用靶向辐射成像和治疗相结合，有可能改变临床医生发现和治疗癌症和罕见疾病的方式，更好地为治疗决策提供信息，并为 ...

14 小时之前 · Telix Pharmaceuticals TLX recently announced a major step in expanding access to its next-generation prostate cancer imaging agent, Gozellix, by selecting Cardinal Health CAH as a key U.S ...

Telix Pharmaceuticals 是一家成立于2015年，总部位于澳大利亚墨尔本的生物制药公司，主要专注于诊断和治疗放射性药物的开发和商业化，在比利时、日本、瑞士和美国均设有国际业务。

1 天前 · Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies.

2025年2月20日 · Grow precision medicine: Prepared for launch of three new products TLX007-CDx (Gozellix ®), TLX101-CDx (Pixclara ®) and TLX250-CDx (Zircaix ®) 4 in 2025 while continuing to increase sales and market share for Illuccix ®.